- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ISR IMMUNE SYSTEM REGULATION Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 9,300 | -3,43 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,247 | -2,54 % | Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why | ||
| ATAIBECKLEY | 6,200 | -0,80 % | Laufende Fusionskontrollverfahren: Eli Lilly and Company, Indianapolis, IN/USA; Erwerb sämtlicher Anteile an und alleiniger Kontrolle über die AtaiBeckley Inc., New York/USA | Datum der Anmeldung:23.07.2026Aktenzeichen:B3-85/26Unternehmen:Eli Lilly and Company, Indianapolis, IN/USA; Erwerb sämtlicher Anteile an und alleiniger Kontrolle über die AtaiBeckley Inc., New York/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| BIOMERIEUX | 69,75 | -2,65 % | BioMerieux H1 Net Sales Slip On Foreign Exchange Impact; Backs Annual Sales Growth Outlook | PARIS (dpa-AFX) - BioMérieux SA (EYWN.MU, BIM.PA), a French biotechnology company, on Tuesday reported an increase in net income for the first half of fiscal 2026, helped by a drop in amortization... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 0,830 | +4,40 % | Bio Green Med Solution, Inc. - S-4/A, Registration of securities, business combinations | ||
| ANAPTYSBIO | 46,000 | -3,60 % | ANAPTYSBIO, INC - 8-K, Current Report | ||
| GENUS | 26,200 | +2,34 % | Telekoms, Bau und Pharma: 32 Aktien gegen den KI-Kater: Berenbergs Rezept für nervöse Anleger | Rechenzentren werden gestrichen, Gesetze gegen KI häufen sich, die Bewertungen bleiben hoch. Berenberg zeigt, mit welchen 32 Aktien Anleger dem Tech-Trubel entkommen können.Die KI-Rallye war lange die... ► Artikel lesen | |
| MEIRAGTX | 10,600 | +1,92 % | MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec) | MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investmentFollowing regulatory approval, Oberland Capital to receive low single-digit capped royalties on... ► Artikel lesen | |
| AKESO | 10,435 | +0,10 % | Akeso, Inc.: Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer | HONG KONG, July 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase Ib/II... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 2,080 | -13,33 % | XTL Biopharmaceuticals Ltd.: XTL Completed the Acquisition of Psyga Bio Ltd. | expands its IP portfolio to clinical-stage biopharmaceutical assets XTL Biopharmaceuticals (XTL) Completes the Acquisition of Psyga Bio and Establishes Psychedelic Biotechnology Platform At a historic... ► Artikel lesen | |
| ABIONYX PHARMA | 1,834 | -2,65 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| MAAT PHARMA | 2,770 | -2,46 % | MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,056 | -1,76 % | Isofol Medical AB: Isofol initiates last dose cohort in ongoing phase Ib study with arfolitixorin | GOTHENBURG, Sweden, July 8, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed the third dose level in the dose-escalation part of the phase... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,07 | -0,10 % | AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates | ||
| KINIKSA PHARMACEUTICALS | 74,34 | -4,94 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen |
Das Unternehmen ISR IMMUNE SYSTEM REGULATION HOLDING AB kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISR IMMUNE SYSTEM REGULATION HOLDING AB finden Sie auf Wallstreet Online.